Trials / Unknown
UnknownNCT06142344
Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer Patients
The Added Value of 166Ho Trans-arterial Radioembolization to Systemic Therapy in Liver Metastatic Breast Cancer Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 13 (estimated)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this multicentre clinical pilot study is to investigate the feasibility of the addition of Ho-166 radioembolization to chemotherapy in patients with liver metastastic breast cancer. Participants will receive a mapping angiography and Ho-166 radioembolization. Chemotherapy will be stopped 2-5 prior to radioembolization and continuation of chemotherapy will be evaluated at 2 weeks post-radioembolization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Quiremspheres™ | The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization. |
Timeline
- Start date
- 2023-10-19
- Primary completion
- 2025-10-19
- Completion
- 2026-01-19
- First posted
- 2023-11-21
- Last updated
- 2023-11-21
Locations
2 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT06142344. Inclusion in this directory is not an endorsement.